Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)

China flag China · Delayed Price · Currency is CNY
26.92
+0.38 (1.43%)
At close: Apr 30, 2026
7.64%
Market Cap 3.36B
Revenue (ttm) 373.85M
Net Income (ttm) -76.61M
Shares Out 126.54M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,034,400
Average Volume 2,311,651
Open 26.95
Previous Close 26.54
Day's Range 26.67 - 27.60
52-Week Range 24.96 - 41.50
Beta -0.59
RSI 43.37
Earnings Date Apr 28, 2026

About SHE:301089

Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; and other APIs and pharmaceutical intermediates covering antiviral, anti-tumor, and nervous system. The company was founded in 2001 and is based in Xinxi... [Read more]

Sector Healthcare
Founded 2001
Employees 1,543
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301089
Full Company Profile

Financial Performance

In 2025, SHE:301089's revenue was 378.34 million, a decrease of -10.28% compared to the previous year's 421.69 million. Losses were -69.66 million, 250.3% more than in 2024.

Financial Statements

News

There is no news available yet.